The Journal of infectious diseases · 2026
Real-World Effectiveness of Sequential Pneumococcal Vaccination in Older Adults: A Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan Yong Yi, Ho Reen Wan Li, Lim Jue Tao, Chiew Calvin J, Lim Soon Kok, Lye David Chien Boon, Tan Kelvin Bryan, Wee Liang En
Аннотация
BACKGROUND: While the real-world effectiveness of various pneumococcal vaccine formulations has been individually evaluated, comparative evaluations of 13-valent pneumococcal conjugate vaccine (PCV13)/23-valent pneumococcal polysaccharide vaccine (PPSV23) and combinations thereof are limited. We evaluated the real-world vaccine effectiveness of PCV13 alone, PPSV23 alone, or PCV13 followed by PPSV23 amongst older adults.
METHODS: A population-based retrospective cohort study, including all adult Singaporeans aged ≥65 to 89 years from 1 January 2020 to 31 July 2024. The time to event from cohort enrollment to pneumococcal-related disease and all-cause pneumonia was measured, considering death as a competing risk. Cox regression models were used to estimate cause-specific hazards, with PCV13 alone, PPSV23 alone, and PCV13 followed by PPSV23 incorporated into models as time-dependent covariates. Vaccination status was assessed using the National Immunisation Registry; outcomes were identified using national healthcare claims data.
RESULTS: A total of 656 337 older Singaporeans were included; 348 831 (53.1%) remained unvaccinated by the study end date. Sequential PCV13 followed by PPSV23 significantly protected against pneumococcal-related disease (adjusted hazard ratio, 0.22 [95% confidence interval, .06-.76]), pneumonia hospitalizations (0.94 [.91-.97]), and all-cause mortality (0.70 [.67-.74]). While PCV13 alone also reduced the risk of pneumonia hospitalization (adjusted hazard ratio, 0.96 [95% CI, .92-.99]) and all-cause mortality (0.86 [95% confidence interval, .83-.89]), vaccine effectiveness estimates were numerically lower than with sequential vaccination. For sequential vaccination, no significant waning of protection against all-cause pneumonia hospitalization or death was observed; a longer time interval (≥365 days) between PCV13 and PPSV23 was associated with a numerically lower risk of all-cause pneumonia hospitalization or death than a shorter interval (<365 days).
CONCLUSIONS: PCV13 followed by PPSV23 was associated with lower risk of pneumococcal-related disease, pneumonia, and all-cause mortality, supporting recommendations for sequential vaccination in older adults.
METHODS: A population-based retrospective cohort study, including all adult Singaporeans aged ≥65 to 89 years from 1 January 2020 to 31 July 2024. The time to event from cohort enrollment to pneumococcal-related disease and all-cause pneumonia was measured, considering death as a competing risk. Cox regression models were used to estimate cause-specific hazards, with PCV13 alone, PPSV23 alone, and PCV13 followed by PPSV23 incorporated into models as time-dependent covariates. Vaccination status was assessed using the National Immunisation Registry; outcomes were identified using national healthcare claims data.
RESULTS: A total of 656 337 older Singaporeans were included; 348 831 (53.1%) remained unvaccinated by the study end date. Sequential PCV13 followed by PPSV23 significantly protected against pneumococcal-related disease (adjusted hazard ratio, 0.22 [95% confidence interval, .06-.76]), pneumonia hospitalizations (0.94 [.91-.97]), and all-cause mortality (0.70 [.67-.74]). While PCV13 alone also reduced the risk of pneumonia hospitalization (adjusted hazard ratio, 0.96 [95% CI, .92-.99]) and all-cause mortality (0.86 [95% confidence interval, .83-.89]), vaccine effectiveness estimates were numerically lower than with sequential vaccination. For sequential vaccination, no significant waning of protection against all-cause pneumonia hospitalization or death was observed; a longer time interval (≥365 days) between PCV13 and PPSV23 was associated with a numerically lower risk of all-cause pneumonia hospitalization or death than a shorter interval (<365 days).
CONCLUSIONS: PCV13 followed by PPSV23 was associated with lower risk of pneumococcal-related disease, pneumonia, and all-cause mortality, supporting recommendations for sequential vaccination in older adults.